Acquisition / mergerNotableFiled on BSE ·

Entero Healthcare Q4 FY26 consolidated profit Rs 451.28 million vs Rs 314.22 million

Entero Healthcare Solutions · Retailing

Arthneeti Research DeskPublished 1 min read
₹45.1 CrAcquisition / merger

Key highlights

  • Consolidated revenue from operations for the year ended March 31, 2026 was Rs. 65,912.12 million; profit before tax was Rs. 1,793.36 million.
  • Board approved re-appointment of three independent directors for five years, Aug 25, 2026 to Aug 24, 2031, subject to shareholder approval at the AGM.
  • Board approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals via subsidiary Sai Pharma Distributors by slump sale/BTA; no amount is given.

Why it's rated notable: the year-on-year change is 44% (20% to 50%)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Announcement under Regulation 30 (LODR)-Change in Management

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Entero Healthcare Solutions

Other acquisition / merger filings this fortnight

All acquisition / merger filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.